A

Business profile & competitive position

Agilent Technologies, Inc. operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. The company delivers application-focused solutions for life sciences, diagnostics and applied markets, including instruments, software, services and consumables across the laboratory workflow. Following a November 2024 reorganization, Agilent now reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Sales are driven primarily through a direct sales force, supplemented by distributors, resellers, manufacturers’ representatives and e-commerce.

The company’s profitability metrics give a concrete read on its competitive position. Agilent’s net margin is 19.5% and its return on equity is 20.5%. For an instrumentation and diagnostics business, combined returns at that level generally indicate strong pricing power, recurring consumables revenue, an entrenched installed base, and multi-year service agreements. Those factors help explain why ROE sits above 20% despite a global, R&D-intensive operation. At the same time, a beta of 1.21 shows the stock still swings more than the broader market, which means the business has not escaped cyclicality tied to pharmaceutical, biotech and industrial capital spending.

Financial posture

As of the October 12, 2026 snapshot, Agilent carried a market capitalization of $48.3 billion and traded at a P/E ratio of 33.6. The stock price was $171.065, with a 50-day EMA of $157.12 and an RSI of 63.2 — comfortably above the short-term moving average but not in technically overbought territory.

The valuation numbers tell a specific story. A 33.6 P/E paired with a 19.5% net margin and 20.5% ROE means Agilent is both highly profitable and priced at a meaningful premium to the broader market. The margin profile supports the idea that the company can sustain strong returns; the 33.6 multiple means the market is already assuming that strength continues. A beta of 1.21 adds an important layer: any earnings or macro surprise is likely to move the stock more than the overall market, so the same fundamental result can produce larger price swings here than in a lower-beta name.

Strategic priorities & outlook

Agilent’s most recent 10-K filing, summarized from its own SEC disclosure, frames the company around three reportable segments and a customer-centric go-to-market model. Its stated priorities are:

• Realign into three segments — Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets — to support a market-focused strategy.
• Expand the liquid chromatography application space with new columns, new services and ongoing instrument and software product enhancements.
• Continue improving mass spectrometry portfolio capabilities, including performance, sensitivity, precision, robustness, ease of use and onboard intelligence.
• Advance software and service solutions to help customers operate a digitally connected smart lab that leverages data analytics, artificial intelligence and robotics.

Operationally, Agilent employed approximately 18,100 people worldwide as of October 31, 2025 — about 6,300 in Life Sciences and Diagnostics Markets, 7,400 in Agilent CrossLab and 2,500 in Applied Markets. The business is supported by centralized order fulfillment and supply chain operations plus a global infrastructure organization that provides shared services in finance, IT, legal, procurement, workplace and HR. Primary R&D and manufacturing sites are located in California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S., and internationally in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom. That footprint provides global diversification but also creates dependencies on cross-border logistics and currency translation.

Macro & geopolitical exposure

Because Agilent sits in Healthcare / Medical – Diagnostics & Research, its macro exposures align with the rhythms of regulated, capital-intensive research tools rather than consumer discretionary demand. Regulatory approval and compliance timelines for laboratory instruments and diagnostic workflows can affect product launches and revenue recognition. Reimbursement and health-care spending decisions in major markets influence diagnostic-system demand. And because Agilent sells heavily into pharmaceutical and biotech R&D, any pullback in biotech funding or corporate R&D budgets can pressure instrument orders.

Trade policy is another genuine exposure. With manufacturing and R&D sites spanning the U.S., China, Europe and elsewhere, tariffs, export controls or supply-chain disruptions can affect both component costs and customer access. Currency translation matters as well: a global installed base means revenue and profits are exposed to dollar cross-rates. More broadly, the industry’s push toward automation, AI-driven analytics and smart-lab workflows creates an adoption-cycle risk — equipment spending rises when labs feel confident about long-term efficiency gains and tightens when budgets are conservative.

Recent developments

The latest news around Agilent mixes product execution, capital-return narrative and valuation debate. On October 1, 2026, Agilent introduced the NovoStation Sample Preparation System for automated flow cytometry workflows, according to businesswire.com — a direct example of the robotics and automation priorities described in its 10-K.

On October 2, 2026, Seeking Alpha included Agilent in a dividend-focused piece, “Dividend Champion, Contender, And Challenger Highlights,” which signals continued attention from income-oriented investors. On October 12, 2026, Zacks asked whether Agilent (A) is outperforming other medical stocks this year, reflecting ongoing sector-relative performance questions rather than a settled conclusion. Earlier, on September 30, 2026, GuruFocus published a DCF analysis titled “Intrinsic Value $120 vs Price $175,” highlighting a wide gap between its modeled fair value and the then-current market price. None of these headlines dictate direction, but together they show the conversation around Agilent has shifted toward relative performance, valuation and automation-driven product launches.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Agilent beat earnings estimates six times, for a beat rate of 86%, with an average earnings surprise of 3%. The average 5-day price move in the trading days after earnings across those quarters is 2.44%, classified as an “up” drift.

Drilling into the most recent four quarters shows why that average can be deceptive. On August 26, 2026, Agilent reported EPS of $1.62 versus an estimate of $1.49, an 8.7% positive surprise. The stock rose 1.68% the next day but then fell 2.38% over the following five days — a beat that quickly reversed. On May 27, 2026, the company delivered EPS of $1.49 against $1.41, a 5.7% beat, and the market reaction was dramatic: the stock jumped 16.87% the next session and 18.61% over the next five days. That one quarter is responsible for most of the positive average post-earnings drift.

By contrast, the February 25, 2026 miss — EPS of $1.36 versus $1.37, a 0.7% negative surprise — produced a next-day drop of 3.01% and a five-day decline of 3.35%, a textbook punishment. More interesting is November 24, 2025: Agilent beat with EPS of $1.59 versus $1.58431, a 0.4% positive surprise, yet the stock gave back its 2.34% next-day gain and finished down 3.12% over the next five days.

The pattern is clear: beating estimates does not guarantee a sustained post-earnings rally. The 86% beat rate shows Agilent usually clears the consensus, but the market’s real expectation — and how the stock reacts over the next one to five sessions — depends on guidance, margin commentary, sector sentiment and whether the surprise was already priced in. The next scheduled report is November 23, 2026, after the close, with a consensus EPS estimate of $1.72 and the stock price at $171.065 heading into the print.

For a deeper dive into how institutional analysts, quant models and options activity are positioning around Agilent ahead of the November 23, 2026 report, review the full institutional verdict on the company.